crv431

The 5th Global NASH Congress will take place in London (in person only) on May 27 and 28. Louise Campbell and scientist/entrepreneur Rachel Zayas, who will cover the Congress for NASH Tsunami, join Ian Rowe and regulars Jörn Schattenberg and Roger Green to discuss some key papers and issues covered there. This conversation starts with Ian Rowe and Jörn Schattenberg sharing their perspectives on how much of the emerging genetics and omics of Fatty Liver disease clinicians need to understand. This transitions into a discussion of the drug development presentations in the meeting and what we stand to learn from these.

Ian Rowe and GenFit Global Diagnostics Leader Suneil Hosmane join Louise and Roger as they keep discussing Day Two of the 4th Global NASH Congress.

On April 29, over 175 NASH stakeholders from across the globe met virtually to hear 20 presentations from leaders in academia and industry. SurfingNASH selected 9 presentations to discuss in a session recorded right after the conference concluded. When the five panelists got together, the discussion extended to 90 minutes...too long for a single episode.

Episode 23 features Suneil Hosmane discussing lifestyle and exercise, Ian Rowe discuss public policy in the US Veterans Health system, and Ian and Roger Green reviewing three developmental drugs discussions from the conference. Louise Campbell lends perspective throughout. Stimulating...engaging..."can't miss."

Naim Alkhouri, Ian Rowe and GenFit Global Diagnostics Leader Suneil Hosmane join Louise Campbell and Roger Green to review presentations from Day Two at the 4th Global NASH Congress.

On April 29, over 175 NASH stakeholders from across the globe met virtually to hear 20 presentations from leaders in academia and industry. SurfingNASH selected 9 presentations to discuss in a session recorded right after the conference concluded. When  the five panelists got together, the discussion extended to 90 minutes...too long for a single episode.

Episode 22 features Naim Alkhouri and Louise Campbell discussing featured presentations on genomics, transcriptomics and the genetics of precision medicine, plus a review of belapectin and non-hepatologist awareness of and commitment to treat NASH and NAFLD.  The conversation features deep dives into drug development and debates on the proper public health strategy for treating NAFLD patients. Stimulating...engaging..."can't miss."

HEP Dynamics will publish the rest of the Day Two reviews in Episode 23 on Saturday, May 1.

Naim Alkhouri and Jörn Schattenberg join Roger and Donna to review the closing session of NASH-TAG 2021, a potpourri of basic science and review of promising drugs earlier in development.

The Saturday afternoon closing session of NASH-TAG 2021 spends half its time discussing basic science issues and the other half with BioPharma company drug developers discussing their promising drugs in development. Last year, this session yielded some real fireworks! On Sunday, join SurfingNASH to sort out how what the data means, how the pieces fit together and what questions will require more exploration. If you send us any questions emerging from Session #4 or the podcast, we will review them in our NASH-TAG wrap-up episode next week.